• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 24, 2018

View Archived Issues

Innate banks $242M as Astrazeneca doubles down on oncology alliance

DUBLIN – Shares in Innate Pharma SA rose by as much as 39 percent during trading Tuesday as the French biotech and its partner, Astrazeneca plc, rejigged their existing oncology alliance, which now guarantees a minimum $241.85 million in cash to Innate, with the potential for a whole lot more – almost $5.2 billion – to come in option fees and milestone payments. Read More

Enterome gets $50M up front in Crohn's pact with Takeda

DUBLIN – Enterome SA is getting $50 million up front plus up to $640 million more in clinical development, regulatory and commercial milestones in a global licensing and co-development deal with Takeda Pharmaceutical Co. Ltd., under which the two companies will jointly take forward its lead drug, EB-8018, which is currently in development for Crohn's disease. Osaka, Japan-based Takeda has also committed to invest $15 million in Paris-based Enterome at a future date. Read More

Pfizer lures Bain to brain in CNS-focused startup Cerevel

Maybe those Pfizer Inc. neuroscience assets weren't so lackluster after all. The New York-based pharma and deep-pocketed partner Bain Capital LP placed a portfolio of eight disclosed preclinical and clinical central nervous system (CNS) candidates into the newco Cerevel Therapeutics LLC and backed them with $350 million in committed capital from funds associated with Bain Capital Private Equity and Bain Capital Life Sciences Read More

Zymeworks paves path to pipeline expansion with $480M-plus Leo Pharma deal

Zymeworks Inc. has been recruited by Denmark's Leo Pharma A/S to help discover and develop new bispecific antibodies for dermatology indications. That the deal's value could exceed $480 million might be the headliner for companies that have yet to capture big pharma's attention. Zymeworks, by contrast, has already inked technology deals with Merck & Co. Inc., Glaxosmithkline plc, Janssen Biotech Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co. and Celgene Corp. Read More

Stoke stoked with $90M as TANGO platform leads, others follow in DS mode

Stoke Therapeutics Inc. CEO Edward Kaye told BioWorld that the company cranked its quest "into turbocharge mode, once we had the animal data [in June] that suggest we were having some pretty significant efficacy results," and clinical work is expected to begin by 2020. Read More

No finish line for data integrity, but each step forward makes an impact

With the growing globalization of clinical trials, greater complexity of study designs and the move from site-centric to patient-centric studies, issues of data integrity loom larger than ever. And those issues continue to evolve, the FDA's David Burrow said Tuesday as he opened the first FDA/MHRA joint workshop on good clinical practices. Read More

Zejula gets Hong Kong nod for second-line ovarian cancer maintenance

HONG KONG – China biopharmaceutical firm Zai Lab Ltd. bagged marketing approval from Hong Kong's Department of Health this week for its PARP inhibitor, Zejula (niraparib), targeting patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian cancer. It is intended for second-line maintenance use for adult ovarian cancer patients. Read More

Can telemedicine, wearables save primary care?

CLEVELAND - How are telemedicine and wearable technologies changing health care and how physicians see patients? That question was the focus of a panel that examined how such emerging technology can play a role in improving primary care. The panel took place during the Cleveland Clinic's 2018 Medical Innovation Summit and was part of the a series of discussions on how technologies, including digital health, are disrupting health care. Read More

Financings

Cel-Sci Corp., of Vienna, Va., said it received almost $8 million through the exercise of warrants to purchase shares of the company's common stock during the past three months. As of Oct. 22, the company said it has 28.27 million shares outstanding. Read More

Earnings

Alkermes plc, of Dublin, reported total revenues of $248.7 million for the third quarter, which included sales of alcohol dependence drug Vivitrol (naltrexone for extended-release injectable suspension) totaling $79.9 million and sales of schizophrenia drug Aristada (aripiprazole lauroxil) totaling $36.1 million. Read More

Other news to note

Purdue Pharma LP, of Stamford, Conn., plans to acquire Spinethera Inc., of Plymouth, Minn., to gain access to Spinethera's products and technology platforms, including its lead asset, SX-600, a microsphere suspension of dexamethasone being developed as an epidural administration for low back pain. Terms of the deal weren't disclosed. Read More

Regulatory front

The FDA, in partnership with international regulatory and law enforcement agencies, this week targeted 465 websites, operated by seven networks, that illegally sell potentially dangerous, unapproved versions of opioid, oncology and antiviral prescription drugs to U.S. consumers. The effort was part of Operation Pangea XI, a global cooperative effort led by Interpol. Read More

Clinical data for Oct. 23, 2018

Read More

Regulatory actions for Oct. 23, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe